

**Title:** A meta-analysis of the transferability of bone mineral density ge from European to African ancestry populations

**Authors:** Michelle S. Yau<sup>1,2</sup>, Allison L. Kuipers<sup>3</sup>, Ryan Price<sup>4</sup>, Aude N Tajuddin<sup>5</sup>, Samuel K. Handelman<sup>6</sup>, Liubov Arbeeveva<sup>7</sup>, Alessandra Che Ching-Ti Liu<sup>10</sup>, David Karasik<sup>1,11</sup>, Babette S. Zemel<sup>12,13</sup>, Struan F.A. G Jordan<sup>7</sup>, Rebecca D. Jackson<sup>15</sup>, Michele K. Evans<sup>5</sup>, Tamara B. Harris Douglas P. Kiel<sup>1,2</sup>

**Affiliations:**

<sup>1</sup> Hinda and Arthur Marcus Institute for Aging Research, Hebrew Senior

<sup>2</sup> Department of Medicine, Beth Israel Deaconess Medical Center and Boston, MA, USA

<sup>3</sup> Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA

<sup>4</sup> Laboratory of Neurogenetics, National Institute on Aging, Bethesda,

<sup>5</sup> Laboratory of Epidemiology and Population Sciences, National Institute MD, USA

<sup>6</sup> Department of Internal Medicine, University of Michigan, Ann Arbor,

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as follows: Yau MS, Kuipers AL, Price R, et al. A meta-analysis of the transferability of bone mineral density ge from European to African ancestry populations. *JAMA*. 2023;329(12):1055-1064. doi:10.1001/jama.2023.1055

<sup>12</sup> Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

<sup>13</sup> Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>14</sup> Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>15</sup> Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

**Funding Sources:** NIAMS R01-AR041398, 5-P60-AR30701, R01-AR041398, 5-P60-AR49465, and 5-P60-AR062760; NIA T32-AG023480 and R01-AG041398; S043, S1734, and S3486; CDC U01DP003206 and U01DP006266; A program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

**Disclosures:** None

## Abstract

Genetic studies of bone mineral density (BMD) largely have been conducted in European ancestry populations. We therefore conducted a meta-analysis of six independent cohorts to determine whether previously reported BMD loci identified in European ancestry populations were transferable to African ancestry populations. We included nearly 100,000 individuals from both genetic data and assessments of BMD. Genotype imputation was performed using the 1000G reference panel. We assessed SNP associations with femoral neck BMD in each cohort separately, then combined results in fixed effects meta-analysis. Where study heterogeneity was high,  $I^2$  index > 60) inverse variance weighted meta-analysis. In secondary analyses, we conducted locus-based analyses of rare variants. The study population age ranged from 12 to 68 years. One cohort included only men and another included only women; proportion of women in the other four cohorts ranged from 40% to 60%. Of 10 BMD loci tested, one locus, 6q25 (*C6orf97*,  $P$ -value= $8.87 \times 10^{-4}$ ) was associated with spine BMD and two loci, 7q21 (*SLC25A13*,  $P$ -value= $2.84 \times 10^{-4}$ ) and 7q31 (*SLC25A13*,  $P$ -value= $2.96 \times 10^{-5}$ ) were associated with femoral neck BMD. Effects were similar to those as previously reported in European ancestry studies and met a Bonferroni-adjusted significance threshold, the criteria for transferability to African ancestry populations. We identified associations that met locus-specific Bonferroni-adjusted  $P$ -value thresholds: 2p23 ( $P$ -value= $3.33 \times 10^{-4}$ ), 11p11 (*DCDC5*,  $P$ -value= $5.35 \times 10^{-5}$ ) and 17p12 (*SLC25A13*,  $P$ -value= $2.96 \times 10^{-5}$ ).

**Keywords:** Genetics research, Human association studies, General p  
Osteoporosis, DXA. Other keywords: BMD, genetics, African ancestry

## Introduction

Osteoporosis is a major public health burden in older adults, affecting approximately 54% of the US adult population 50 years and older <sup>(1)</sup>. It is a skeletal disorder characterized by low bone mass and quality that leads to bone fragility and increased susceptibility to fractures. Assessment of bone mineral density (BMD) utilizing dual-energy X-ray absorptiometry (DXA) is a key to clinical diagnosis of osteoporosis <sup>(2)</sup> and remains the single best method for diagnosis. Among individuals of European ancestry, women experience about twice the fracture rates as men, but sex differences in fracture rates among African Americans are less pronounced. African American men and women have higher bone mineral density and lower fracture rates than similar aged individuals of European ancestry <sup>(5)</sup>. In 2005, 12% of all whites were diagnosed with osteoporosis; this is expected to increase to 21% by 2025 <sup>(6)</sup>. There are ethnic differences in osteoporosis diagnosis and treatment that need be better understood. The pathogenesis and prevention of osteoporotic fractures in older individuals <sup>(7)</sup>.

Genetic factors may contribute to BMD variation within and between ethnic groups <sup>(8)</sup>. BMD has a strong genetic component as demonstrated by heritability estimates ranging from 50% to 85% <sup>(9-13)</sup>, where estimates tend to be higher in twin and other family studies <sup>(16)</sup>. Greater African genetic admixture has been associated with higher bone mass and biomechanically more favorable hip geometry, but larger decreases in bone mass with aging <sup>(14-15)</sup>.

The majority of genetic studies have been conducted in Europe and may not reflect the genetic architecture of BMD in African American populations. A small fraction of BMD loci identified from genetic studies of European populations are transferable (i.e., replicated in non-European populations) <sup>(25,26)</sup>. For example, a GWAS in African American women found that few BMD loci were transferable to African American populations but identified a novel variant in *SVIL* that had not been previously identified in European ancestry populations <sup>(27)</sup>. High transferability of GWAS findings across populations is commonly reported for other complex traits <sup>(24)</sup>. Assuming that most underlying genetic architecture is common and shared across ancestral groups, there still may be differences in genetic architecture and ancestral effects that limit transferability of GWAS findings across ancestry groups <sup>(28)</sup>. To date, few genetics studies of BMD have been conducted in African ancestry populations <sup>(29)</sup>. Genetic studies in African ancestry populations are needed to determine whether previously identified BMD risk loci confer the same disease risk in African ancestry populations and to identify new genetic associations that may have been missed in studies based on European populations.

We therefore conducted the largest meta-analysis of selected BMD loci in multiple independent African ancestry cohorts to determine whether BMD loci identified in European ancestry populations are transferable to African ancestry populations.

femoral neck and/or lumbar spine: the Tobago Bone Health Study (Tobago Bone Health, Aging and Body Composition Study (Health ABC) (n=1,093), Women's Health Initiative (WHI) (n=908), Neighborhoods of Diversity across the Lifespan (HANDLS) (n=908), WHI (n=797), Johnston County Osteoarthritis Project (JoCoOA) (n=797), Mineral Density in Childhood Study (BMDCS) (n=340).

Tobago: The Tobago Bone Health study is a population-based study of the Caribbean island of Tobago <sup>(30)</sup>. Men aged 40 years and older were recruited based on health status except that participants had to be ambulatory, non-institutionalized, and not terminally ill. Men for this analysis were selected to be of African ancestry based on self-report of 1+ African grandparent; non-African ancestry in Tobago is estimated to be <6% <sup>(31)</sup>. Lumbar spine and femoral neck BMD were measured using a QDR4500. The Institutional Review Boards of the University of Pittsburgh and the Ministry of Health and Social Services approved this study, and all participants gave informed consent before data collection.

Health ABC: The Health, Aging and Body Composition study included 1,093 men and women aged 70-79 years at the initial visit focused on identifying factors that contribute to functional decline in older persons in relation to changes in bone mass with age. Participants were recruited from a random sample of white and

age-related health disparities among socioeconomically diverse African Americans in Baltimore <sup>(32)</sup>. Participants were recruited from 13 contiguous neighborhood areas using area probability sampling and randomly selected within strata based on socioeconomic status. BMD measurements from the first examination were included in the analysis. Total body, hip and lumbar spine BMD were measured by Lunar Proton QDR Discovery-A. Machine type was included as a study-specific covariate. All participants provided written informed consent. The protocol was approved by the ethics review board at the National Institute of Environmental Health Sciences.

WHI: The Women's Health Initiative is a long-term national health study that enrolled geographically diverse women aged 50-79 years at the time of study enrollment. The study was designed to address risk factors for diseases that commonly affect postmenopausal women, including cardiovascular disease, cancer, and osteoporosis <sup>(33)</sup>. At study inception, there were two major components to WHI, an observational study and four clinical trials. The observational study included women aged 50-79 years in a prospective cohort study, and randomized women aged 50-79 years into one of four placebo-controlled trials (estrogen, post-menopausal hormone therapies, dietary intervention, or calcium and vitamin D supplementation). Bone mineral density was measured in participants at three clinical centers (Pittsburgh, PA; Birmingham, AL; and Tucson/Phoenix, AZ).



provided written informed consent. Institutional review board approval was obtained from all participating institutions.

JoCoOA: The Johnston County Osteoarthritis Project is a community-based study of white and African American men and women aged 45 years and older living in North Carolina <sup>(38)</sup>. The study was designed to determine racial differences in prevalence and incidence of risk factors associated with the occurrence and progression of osteoarthritis. Participants were recruited by probability sampling, with equal representation of African Americans. Hip and lumbar spine BMD were measured using the Hologic Discovery A densitometers. All participants provided written informed consent. The study was approved by the Institutional Review Boards at the University of North Carolina Schools of Medicine and the Centers for Disease and Control Prevention.

BMDCS: The Bone Mineral Density in Childhood Study is a longitudinal study of normally developing boys and girls aged 5-20 years old who were recruited in 2007 from five clinical centers (Los Angeles, CA; Cincinnati, OH; Omaha, NE; and New York, NY) <sup>(39,40)</sup>. Hip and lumbar spine BMD were measured using dual-energy X-ray absorptiometry (DXA) measurements with either Hologic QDR4500A, QDR4500W, Delphi A or GE Lunar Prodigy densitometers. Values from the baseline assessment were used. On-site DXA was performed at each clinical center. All participants older than 18 years provided written informed consent.

SNP in each locus (i.e., index SNP) and other haplotype tag SNPs to in each locus based on the 1000 genomes reference panel (Phase 1) low call rates ( $<0.9$ ) and deviation from Hardy-Weinberg equilibrium (phased haplotypes and imputed SNPs to the 1000 genomes reference SHAPEIT <sup>(41)</sup> and IMPUTE2 <sup>(42)</sup>, respectively. All other cohorts were wide arrays and similarly imputed to the same 1000 genomes reference JoCoOA were genotyped with the Illumina 1M-Duo platform, WHI was Affymetrix Genome-Wide Human SNP Array 6.0 chip, HANDLS was Infinium II platform, and BMDCS was genotyped with the HumanOmni SNPs with low call rates ( $<97\%$  for Health ABC,  $<95\%$  for HANDLS and WHI,  $<98\%$  for JoCoOA) and deviation from Hardy-Weinberg equilibrium Health ABC,  $<10^{-5}$  for HANDLS, BMDCS, JoCoOA,  $<10^{-4}$  for WHI and prior to imputation.

### *Association Analyses and Meta-Analyses*

We calculated differences in effect allele frequencies between European and our observed African ancestry populations and compared blocks between European and African ancestry populations by dividing

association with lumbar spine and femoral neck BMD in each cohort (1000 Genomes, UK Biobank, and the Rotterdam Study). Models assumed an additive genetic model and were adjusted for sex, age, and BMI. In addition, models were adjusted for study-specific genetic principal components to account for population stratification<sup>(43)</sup> and other study-specific covariates such as education and smoking. SNPs on different machines were used. Boundaries of the loci were defined by the 1000 Genomes European ancestry (EA) $\geq 0.8$ ) furthest up and downstream of the index SNP based on the 1000 Genomes European ancestry reference panel<sup>(44)</sup>. Each cohort performed single-variant GWAS on all autosomal chromosomes and X chromosome using the prepScores approach implemented in the seqMeta R package. We then conducted an inverse-variance weighted meta-analysis of lumbar spine and femoral neck BMD associations with summary statistics from each cohort. Only SNPs with good imputation quality (INFO $\geq 0.8$ ) and common SNPs with minor allele frequencies  $\geq 0.01$  were included. A P-value  $< 0.05$  were considered nominally statistically significant. To account for multiple testing, we used a Bonferroni corrected P-value threshold (P-value $=0.05/56=8.93\times 10^{-4}$ ) if SNPs were in high LD with the index SNP (LD $\geq 0.8$ ) based on the 1000 Genomes African ancestry reference panel. If SNPs were in moderate LD (LD $\geq 0.4$ ,  $r^2_{AA}<0.8$ ) with the index SNP, we used a locus-specific P-value threshold (P-value $=0.05/\text{number of tested SNPs}$ ).

To comprehensively assess the entire allele frequency spectrum, we also conducted locus-based analyses of less common SNPs using an optimally combines the burden and SKAT tests used in rare variant analysis. We included SNPs with good imputation quality ( $INFO \geq 0.7$ ) and less common allele frequencies  $< 0.01$ . To account for multiple testing, we used a Bonferroni value threshold to account for testing 56 independent loci ( $P\text{-value}=0.001786$ ).

Fixed and random effects meta-analyses were implemented with Meta-analysis of Rare Variants (Wide Association Meta-Analysis) software <sup>(46)</sup>. SKAT-O analyses were implemented with the seqMeta R package (<https://cran.r-project.org/web/packages/seqMeta/>).

## Results

We included a total of 4,967 individuals from six African ancestries in the analysis of lumbar spine and/or femoral neck BMD and genotyping data (Table 1). Two cohorts included only men and another cohort, WHI, included only women. The other four cohorts ranged from 52% to 63%. Mean age ranged from 44 to 63 years and weight ranged from 78-86 kg in the adult cohorts. The mean age was 44 years and weight was 44 kg in BMDCS, a pediatric cohort.

We tested 56 loci that were originally identified to be genome-

of high LD ( $r^2_{AA} \geq 0.8$ ) around the index SNP. African ancestry LD blocks were 50% smaller than the LD block size in European ancestry populations (median=16 kb; interquartile range=3 kb to 55 kb) and proportion of African ancestry LD block sizes ranged from 0% to 775% (median=50%; interquartile range=10% to 80%) (Supplementary Table 4). About a third of the loci tested had African ancestry LD blocks that were 70% smaller than the LD block size in European ancestry populations.

At least one SNP in high LD ( $r^2_{AA} \geq 0.8$ ) with the index SNP or the index SNP itself had nominal statistical significance ( $P$ -value  $< 0.05$ ) in fixed effects models for lumbar spine BMD in *C6orf97*, *GPATCH1*, *JAG1*, *KLHDC5/PTHLH*, *MAPT*, *RSPO3*, *SOX9*, *STARD3NL*, *WLS*, *WNT16*, and *ZBTB40* and femoral neck BMD in *ARHGAP1*, *C6orf97*, *ERC/WNT5B*, *GPATCH1*, *SLC25A13*, *SP7*, *WLS*, *WNT16*, and *ZBTB40* (Table 2). All of these SNPs had  $r^2_{AA} < 0.8$ . *ERC1/WNT5B* had shorter LD blocks in African ancestry populations than European ancestry populations (Figure 2, Supplementary Figure 1, Supplementary Table 4). The  $r^2_{AA}$  was low to moderate ( $r^2 < 0.6$ ) for the majority of nominally significant loci. The association with lumbar spine BMD and *ARHGAP1* and *GPATCH1* as well as femoral neck BMD (Table 2). In random effect models, only the association between *GPATCH1* and lumbar spine BMD met nominal significance ( $P$ -value  $< 0.05$ ) but did not meet the significance threshold after correction for multiple testing ( $P$ -value= $8.93 \times 10^{-4}$ ) (Supplementary Table 2).

removal of BMDCS from the meta-analysis, *C6orf97* remained significant for femoral neck BMD and *WNT16* remained significant for femoral neck BMD (Supplementary Table 8). Multiple testing P-value threshold in both fixed and random effects models (Table 8).

Other SNPs in the locus that were not in LD with the index SNP from the GWAS Consortium ( $r^2_{EA} < 0.8$ ) were tested and were required to meet locus-specific genome-wide corrected P-value thresholds (Supplementary Table 1). SNPs in *DCDC5* met genome-wide significance for lumbar spine BMD and SNPs in *C16orf38*, *DCDC5* met locus-wide significance for femoral neck BMD (Table 3). Study heritability was moderate ( $h^2 < 60$ ) for the majority of loci except *C16orf38* and *FAM9B* for femoral neck BMD. In random effects models, these associations did not remain significant at the genome-wide threshold (Supplementary Table 9). Only two SNPs, rs978751 and rs111111111 in *DCDC5* were previously assessed in GEFOSII (Supplementary Table 10). In secondary analyses, after removal of BMDCS from the meta-analysis, SNPs in *DCDC5* were genome-wide significant for lumbar spine BMD and SNPs in *DCDC5* and *LRP11* were genome-wide significant for femoral neck BMD (Supplementary Table 11).

In secondary gene-based analyses of rare variants (minor allele frequency < 1%), we found significant associations with lumbar spine BMD in *AKAP11*, *SLC25A13*, *STARD3*

tested 56 BMD loci originally identified in the largest GEFOS Consortium study. We found that only three loci, *C6orf97* (also known as *CCDC170*), *SLC25A13*, and *WNT16* were transferable to African ancestry populations. We also found significant associations with BMD for *SMG6*, and *LRP5* that were not tagged by European ancestry index SNPs. This suggests there is between population heterogeneity in tag SNPs for BMD. Further, we found evidence that rare genetic variants in *AKAP11*, *MBL2*, *MEPE*, *SLC25A13*, and *TNFRSF11A* were associated with BMD, though these loci did not meet the genome-wide significance threshold for significance after correction for multiple testing. Our results are consistent with other studies that have shown low transferability of BMD loci between European and African ancestry backgrounds and underscore the need to consider differences in genetic architecture between populations when assessing targeted interventions and genetic risk prediction. Larger genetic studies of BMD in African ancestry populations compared to European ancestry populations will be needed to overcome power limitations of our study, and to identify other loci that are transferable between populations and to identify population-specific variants.

While only three loci, *C6orf97*, *SLC25A13*, and *WNT16*, reached genome-wide significance for transferability, we found 17 other loci that reached a less stringent threshold for transferability, which all except two loci had effects in the same direction as that reported in the

our finding that femoral neck BMD had more associations than lumbar spine BMD in the same direction of effect as European ancestry populations. Our study was the first to identify 20 associations at genome-wide significance thresholds for all previously identified loci. This suggests that with a larger sample size, more loci transferable between European and African ancestry may be identified.

Our findings are consistent with other genetic studies of non-European populations. In Asian populations, at least 16 known loci discovered in European and African ancestry populations associated with BMD, including *AKAP11*, *C6orf97*, *C17orf53*, *CTNNE3*, *CTNNA3*, *MEPE*, *SLC25A13*, *SPTBN1*, *STARD3NL*, *SOX6*, *TNFRSF11A*, *TNFRSF11B*, *WNT16*, and *ZBTB40* <sup>(25,26,48)</sup>. We identified 20 loci associated with BMD, of which 16 were also associated in Asian populations. The three loci that met our criteria for transferability between European and African ancestry, *C6orf97*, *SLC25A13*, *STARD3NL*, *WLS*, and *ZBTB40*, were also associated in Asian populations. The three loci that met our criteria for transferability between European and African ancestry, *C6orf97*, *SLC25A13*, and *WNT16*, were also found to be associated with BMD at genome-wide significance in an African ethnic genome-wide association study, though this study only included African American women <sup>(49)</sup>. Another study showed that SNPs in *WNT16* were associated with BMD in premenopausal women, which were replicated in a study that included a small sample of African American women <sup>(29)</sup>. On the other hand, *WNT16* has been associated with fracture risk in European populations <sup>(19)</sup>, but



cortical thickness and increased cortical porosity but does not affect t  
Similarly, in humans, genetic variants in *WNT16* are associated with c  
Overexpression of *WNT16* in mice increases bone mineral density bu  
bone loss <sup>(52-54)</sup>. The function of *C6orf97* (also referred as *CCDC170*)  
implicated in studies of breast cancer. *C6orf97* is located near the ge  
receptor 1. Estrogen plays an important role in bone homeostasis an  
attenuating bone resorption through estrogen receptor  $\alpha$  in osteoclast  
*WNT16* may play a critical role in acquisition of peak cortical bone ma  
at the early stages of puberty, African American children have greater  
density, mass and size compared to those of European ancestry <sup>(56,57)</sup>  
the possibility that factors related to acquisition and maintenance of c  
particularly relevant to African ancestry populations.

We acknowledge that there are limitations to our study. The s  
designed to determine genome-wide associations, as the largest cont  
limited genotyping of 56 loci selected based on their genome-wide sig  
BMD in the previously published, largest GWAS meta-analysis of fem  
spine BMD to date <sup>(19)</sup>. Our original intent was not to discover new loc  
approach, but rather to determine whether already-verified European

ancestry populations since these variants may not necessarily confer which could be attributed to differences in allele frequencies between ancestry populations and allelic heterogeneity.

Additionally, despite assembling the largest meta-analysis of r with African ancestry, we still had limited power to detect all previous loci, let alone an agnostic GWAS. Due to limited sample size, the intent for new discovery, but rather to determine racial differences in variants already been identified. Large GWAS for new discovery in multiple an direction for the bone field. Interpretation of our findings are also com tagging SNPs that may not necessarily capture all variation in a locus causal variants. However, most variants identified by GWAS are com ancient in origin and shared by different populations <sup>(59)</sup>. Assuming th sufficiently tagged by one or more SNPs in the LD block, we were ab association for several loci since the majority of LD blocks were short European ancestry populations. Most loci had associations in the sam previously reported associations and are likely transferable to African though there may be effect size heterogeneity that impacted our abilit effects. We cannot exclude the possibility that there may be populatio

adolescence and there is high familial resemblance for most bone traits. Despite these limitations, our study provides the first insights into the underlying BMD in African ancestry populations. Additionally, the limited genetic diversity of populations other than those of European ancestry continue to be a barrier to a greater expansion of the field to include large numbers of other ethnicities.

In summary, we conducted the largest African-ancestry meta-analysis of independent samples, we identified three BMD loci, *C6orf97*, *SLC25A38*, and *SLC25A38*, transferable to African ancestry populations. Larger genome wide association and whole genome sequencing studies in African ancestry populations will identify other transferable BMD loci and population-specific variants that may inform targeted interventions and genetic risk prediction for osteoporosis in African ancestry populations.

### **Acknowledgments**

Authors' roles: Study design: MSY, YH, CTL, DK, DPK. Study conduct: MSY, BSZ, SFAG, JMJ, RDJ, MKE, TBH, JMZ, and DPK. Data analysis: MSY, BSZ, SKH, LA, AC. Data interpretation: all. Drafting manuscript: MSY. Revising manuscript: all. Approving final version of manuscript: all. MSY takes responsibility for the content of the manuscript.

## References

1. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. Prevalence of osteoporosis and low bone mass in the United States: prevalence of osteoporosis and low bone mass in the United States: prevalence of osteoporosis and low bone mass in the United States. *J Bone Miner Res*. 2014;29(11):2520-6. Epub 2014/04/29.
2. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*. 2002;359(9321):1929-36. Epub 2002/06/12.
3. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. A global strategy for the primary prevention of BMD for hip and other fractures. *J Bone Miner Res*. Jul 2005;20(7):711-30. Epub 2005/06/09.
4. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. *Lancet*. May 18 2002;359(9319):1761-7. Epub 2002/06/07.
5. Cauley JA. Defining ethnic and racial differences in osteoporosis. *Clin Orthop Relat Res*. Jul 2011;469(7):1891-9. Epub 2011/03/23.
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Browner WS, et al. The global burden of osteoporosis: estimates and economic burden of osteoporosis-related fractures in the United States. *J Bone Miner Res*. Mar 2007;22(3):465-75. Epub 2006/12/06.
7. Cauley JA. Public health impact of osteoporosis. *J Gerontol A Biol Sci Biomed Sci*. 2013;68(10):1243-51. Epub 2013/08/02.
8. Ferrari S, Rizzoli R, Slosman D, Bonjour JP. Familial resemblance in bone mass is expressed before puberty. *J Clin Endocrinol Metab*. Feb 1998;78(2):403-7. Epub 1998/02/19.
9. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. *Endocr Rev*. 2010;31(1):62. Epub 2010/05/01.
10. Slemenda CW, Turner CH, Peacock M, Christian JC, Sorbel J, Reisterer T, et al. The genetics of proximal femur geometry, distribution of bone mass, and bone mineral density. *Osteoporos Int*. 1996;6(2):178-82. Epub 1996/01/01.
11. Smith DM, Nance WE, Kang KW, Christian JC, Johnston CC, Reisterer T, et al. Determining bone mass. *J Clin Invest*. Nov 1973;52(11):2800-10.
12. Gueguen R, Jouanny P, Guillemin F, Kuntz C, Pourel J, Siest A, et al. A principal component and variance components analysis of bone mineral density in the elderly. *J Bone Miner Res*. Dec 1995;10(12):2017-22. Epub 1995/12/01.
13. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. *J Bone Miner Res*. Jan 1993;8(1):1-9. Epub 1993/01/01.
14. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC, Reisterer T, et al.

19. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci associated with risk of fracture. *Nat Genet.* May 2012;44(5):49-56. Epub 2012/04/25.
20. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai F, et al. Genetic influences on osteoporosis in humans and mice. *Nat Commun.* 2019;51(2):258-66. Epub 2019/01/02.
21. Kim SK. Identification of 613 new loci associated with heel bone mineral density and polygenic risk score for bone mineral density, osteoporosis and fracture. *Nat Commun.* 2018;13(7):e0200785. Epub 2018/07/27.
22. Medina-Gomez C, Chesi A, Hepple DH, Zemel BS, Yin JL, Karlamangla AS, et al. Genetic Variants that Contribute to Ethnic and Developmental Differences in Skeletal Structure in Diverse Populations: Assessment of Evolutionary Selection Pressures. *PLoS Genet.* 2015;32(11):2961-72. Epub 2015/08/01.
23. Adeyemo A, Rotimi C. Genetic variants associated with complex traits show wide variation across multiple populations. *Public Health Genomics.* 2009;12(1):Epub 2009/05/15.
24. Marigorta UM, Navarro A. High trans-ethnic replicability of GWAS hits and common causal variants. *PLoS Genet.* Jun 2013;9(6):e1003562.
25. Styrkarsdottir U, Halldorsson BV, Gudbjartsson DF, Tang NL, et al. European bone mineral density loci are also associated with bone mineral density in African populations. *PLoS One.* Oct 7 2010;5(10):e13217. Epub 2010/10/07.
26. Liu JM, Zhang MJ, Zhao L, Cui B, Li ZB, Zhao HY, et al. Analysis of osteoporosis susceptibility genes in Han Chinese women. *J Clin Endocrinol.* 2010;95(9):E112-20. Epub 2010/06/18.
27. Taylor KC, Evans DS, Edwards DRV, Edwards TL, Sofer T, Li J, et al. Association study meta-analysis of clinical fracture in 10,012 African Americans. *Bone Rep.* Dec 2016;5:233-42. Epub 2017/06/06.
28. Ntzani EE, Liberopoulos G, Manolio TA, Ioannidis JP. Consistent genetic associations across major ancestral groups. *Hum Genet.* Jul 2011;121(12):21. Epub 2011/12/21.
29. Koller DL, Ichikawa S, Lai D, Padgett LR, Doheny KF, Pugh EA, et al. Association study of bone mineral density in premenopausal European women and replication in African-American women. *J Clin Endocrinol.* 2010;95(4):1802-9. Epub 2010/02/19.
30. Hill DD, Cauley JA, Sheu Y, Bunker CH, Patrick AL, Baker CE, et al. Bone mineral density in men of African ancestry: the Tobago bone health study. *J Clin Endocrinol.* 2007;98(1):102-10. Epub 2007/01/10.

35. LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson AR. Bone geometry and incidence of hip fracture in postmenopausal women: is there a link with conventional bone mineral density? *Osteoporos Int*. Jun 2010;20(6):1007-15. Epub 2009/09/17.
36. Chen Z, Maricic M, Pettinger M, Ritenbaugh C, Lopez AM, Bunker RK, et al. Osteoporosis and rate of bone loss among postmenopausal women with breast cancer. *Cancer*. Oct 1 2005;104(7):1520-30. Epub 2005/08/20.
37. Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski RT, et al. Bone mineral density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. *Cancer*. Sep 1 2008;113(5):907-15. Epub 2008/07/31.
38. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, White LR, et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. *Arthritis Rheumatology*. Jan 2007;34(1):172-80.
39. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, et al. Bone mineral density in childhood study: bone mineral content and areal bone mineral density by sex, and race. *J Clin Endocrinol Metab*. Jun 2007;92(6):2087-94. Epub 2007/05/23.
40. Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shinar D, et al. Bone mineral reference curves for bone mineral content and areal bone mineral density by age and sex for black and non-black children: results of the bone mineral density in childhood study. *J Clin Endocrinol Metab*. Oct 2011;96(10):3111-20. Epub 2011/09/22.
41. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nature methods*. Feb 2012;9(2):179-81.
42. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet*. 2009;5(6):e1000529.
43. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. Aug 2006;38(8):904-9. Epub 2006/07/25.
44. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison RP, et al. An international reference genome for human genetic variation. *Nature*. Oct 1 2015;526(7568):68-75. Epub 2015/10/04.
45. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. A unified approach for rare-variant association testing with applications to case-control whole-exome sequencing studies. *Am J Hum Genet*. 2012;91(2):224-37.

51. Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, Pate... influences bone mineral density, cortical bone thickness, bone... osteoporotic fracture risk. *PLoS Genet.* Jul 2012;8(7):e100274.
52. Alam I, Alkhouli M, Gerard-O'Riley RL, Wright WB, Acton D, G... Specific Overexpression of Human WNT16 Increases Both Co... Bone Mass and Structure in Mice. *Endocrinology.* Feb 2016;1... 2015/11/20.
53. Ohlsson C, Nilsson KH, Henning P, Wu J, Gustafsson KL, Por... overexpression partly protects against glucocorticoid-induced... *Endocrinol Metab.* Jun 1 2018;314(6):E597-E604. Epub 2018/...
54. Alam I, Oakes DK, Reilly AM, Billingsley C, Sbeta S, Gerard-C... Overexpression of WNT16 Does Not Prevent Cortical Bone Lo... Treatment in Mice. *JBMR Plus.* Apr 2019;3(4):e10084. Epub 2...
55. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igar... prevents bone loss via estrogen receptor alpha and induction... osteoclasts. *Cell.* Sep 7 2007;130(5):811-23. Epub 2007/09/07...
56. Leonard MB, Elmi A, Mostoufi-Moab S, Shults J, Burnham JM... sex, race, and puberty on cortical bone and the functional mus... adolescents, and young adults. *J Clin Endocrinol Metab.* Apr 2... 2010/02/17.
57. Warden SJ, Hill KM, Ferreira AJ, Laing EM, Martin BR, Hausma... differences in cortical bone and their relationship to biochemic... White children in the early stages of puberty. *Osteoporos Int.* ... Epub 2012/10/25.
58. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nat*... 2016;538(7624):161-4. Epub 2016/10/14.
59. Fu J, Festen EA, Wijmenga C. Multi-ethnic studies in complex... Oct 15 2011;20(R2):R206-13. Epub 2011/09/06.
60. Mitchell JA, Chesni A, Elci O, McCormack SE, Roy SM, Kalkwa... Scores Implicated in Adult Bone Fragility Associate With Pedia... *Miner Res.* Apr 2016;31(4):789-95. Epub 2015/11/18.

Table 1. African-ancestry cohort characteristics

	Tobago	HABC	HANDLS	WHI
N	1,414	1,093	908	797
% Female	0	57.4	55.2	100
Age in years (SD)	58.8 (10.4)	73.4 (2.9)	48.7 (8.9)	68 (7.1)
Weight in kg (SD)	84.5 (15.9)	77.8 (19.0)	83.6 (19.5)	82.8 (18.8)

HABC=Health, Aging, and Body Composition; HANDLS=Healthy Aging in across the Life Span Study; WHI=Women's Health Initiative; JoCoOA=JoCoOA Project; BMDCS=Bone Mineral Density in Childhood Study



Table 2. Lead SNP associations in BMD loci (P-value &lt; 0.05 in fixed effects models)

							Lumbar Spine	
Locus	Lead SNP	Closest Gene(s)	A1	A2	Freq1 in EA	Freq1 in AFR	Beta	P-value
1p31.3	rs36100617	<i>WLS</i>	g	-	0.63	0.76	<b>0.01</b>	<b>2.74×10<sup>-2</sup></b>
1p36.12	rs10493013	<i>ZBTB40</i>	c	t	0.17	0.28	<b>0.01</b>	<b>3.15×10<sup>-2</sup></b>
3q25.31	rs344081	<i>LEKR1</i> <sup>a,c</sup>	t	c	0.88	0.47	<b>0.01</b>	<b>1.48×10<sup>-2</sup></b>
4p16.3	rs56079856	<i>IDUA</i>	t	g	0.17	0.11	<b>-0.01</b>	<b>2.46×10<sup>-2</sup></b>
6q22.32	rs13204965	<i>RSPO3</i> <sup>a</sup>	a	c	0.76	0.95	-0.02	7.49×10 <sup>-3</sup>
6q25.1	rs4869745	<i>C6orf97</i> <sup>b</sup>	t	c	0.29	0.69	<b>-0.01</b>	<b>8.87×10<sup>-2</sup></b>
7p14.1	rs6959212	<i>STARD3NL</i> <sup>a</sup>	t	c	0.36	0.35	<b>-0.01</b>	<b>2.23×10<sup>-2</sup></b>
7q21.3	rs4342521	<i>SLC25A13</i>	g	t	0.64	0.81	<b>0.01</b>	<b>1.16×10<sup>-2</sup></b>
7q31.31	rs10242100	<i>WNT16</i> <sup>b</sup>	a	g	0.74	0.63	<b>-0.02</b>	<b>1.88×10<sup>-2</sup></b>
11p11.2	rs10769205	<i>ARHGAP1</i> <sup>d</sup>	g	a	0.29	0.82	<b>0.01</b>	<b>2.56×10<sup>-2</sup></b>
11p14.1	rs11030048	<i>LIN7C</i>	t	c	0.48	0.86	0.01	2.23×10 <sup>-2</sup>
12p11.22	rs7953528	<i>KLHDC5/PTHLH</i> <sup>a,c</sup>	a	t	0.16	0.05	<b>-0.02</b>	<b>3.39×10<sup>-2</sup></b>
12p13.33	rs35223785	<i>ERC1/WNT5B</i> <sup>b</sup>	a	g	0.73	0.81	<b>-0.01</b>	<b>5.21×10<sup>-2</sup></b>
12q13.13	rs10783573	<i>SP7</i> <sup>b</sup>	a	g	0.67	0.41	<b>-0.01</b>	<b>5.28×10<sup>-2</sup></b>
14q32.32	rs7145113	<i>MARK3</i> <sup>b</sup>	g	a	0.36	0.17	<b>-0.01</b>	<b>2.03×10<sup>-2</sup></b>
16p13.11	rs4085155	<i>NTAN1</i> <sup>a</sup>	a	a	0.67	0.66	<b>-0.00</b>	<b>1.76×10<sup>-2</sup></b>

Table 3. Locus-wide significant SNPs not in LD with the GEFOS Consortium index SNP in fixed effect

Locus	SNP	Closest Gene(s)	r <sup>2</sup> in EA <sup>a</sup>	r <sup>2</sup> in AA <sup>a</sup>	A1	A2	Freq1	Lumbago	
								Beta	P
11p14.1	rs7950105	<i>DCDC5</i>	0.62	0.14	t	c	0.81	0.02	5.
11p14.1	rs2145795	<i>DCDC5</i>	0.60	0.01	a	g	0.67	0.01	8.
11p14.1	rs650489	<i>DCDC5</i>	0.61	0.13	a	g	0.18	-0.02	1.
11p14.1	rs36122686	<i>DCDC5</i>	0.63	0.15	a	at	0.82	0.02	1.
11p14.1	rs67243215	<i>DCDC5</i>	0.63	0.15	c	t	0.82	0.02	2.
11p14.1	rs978751	<i>DCDC5</i>	0.62	0.10	g	a	0.55	0.01	3.
17p13.3	rs79682102	<i>SMG6</i>	0.00	0.00	g	a	0.96	-0.04	2.
16p13.3	rs66725354	<i>C16orf38</i> <sup>b</sup>	0.36	0.02	g	a	0.88	0.01	1.
Xp22.31	rs5934498	<i>FAM9B</i>	0.13	0.20	t	c	0.37	0.02	7.
Xp22.31	rs12863157	<i>FAM9B</i> <sup>b</sup>	0.15	0.19	g	t	0.36	0.02	7.
Xp22.31	rs1919627	<i>FAM9B</i> <sup>b</sup>	0.13	0.24	a	g	0.36	0.02	1.
Xp22.31	rs5978281	<i>FAM9B</i>	0.13	0.21	a	g	0.39	0.01	3.
11q13.2	rs111507948	<i>LRP5</i>	0.03	0.00	c	g	0.88	0.01	5.
11q13.2	rs12793818	<i>LRP5</i>	0.03	0.00	c	t	0.88	0.01	5.
11q13.2	rs12793822	<i>LRP5</i>	0.03	0.00	c	t	0.88	0.01	5.

Table 4. SKAT-O rare variant associations in BMD loci (P-values &lt; 0.


	Gene	P-value	Number of SNPs*
Lumbar spine BMD	<i>AKAP11</i>	$2.32 \times 10^{-2}$	2,228
	<i>SLC25A13</i>	$3.03 \times 10^{-2}$	1,396
	<i>STARD3NL</i>	$3.35 \times 10^{-2}$	1,684
	<i>TNFRSF11A</i>	$4.71 \times 10^{-2}$	1,018
Femoral neck BMD	<i>MBL2</i>	$4.09 \times 10^{-2}$	506
	<i>MEPE</i>	$3.15 \times 10^{-2}$	1,897
	<i>TNFRSF11A</i>	$3.18 \times 10^{-3}$	1,018

\*SNPs included have minor allele frequencies < 0.01


## Figure Legends

Figure 1. Distribution of African ancestry linkage disequilibrium block sizes. We identified linkage disequilibrium (LD) blocks around index BMD SNP in African and European ancestry ( $r^2_{EA} \geq 0.8$ ) populations. A proportion was derived from the African ancestry LD block size by the European ancestry LD block size. A smaller proportion indicates that the African ancestry LD block is much smaller than the LD block size in European populations, while a larger proportion indicates that the African ancestry LD block size is similar to the European ancestry block size.

Figure 2. African-ancestry meta-analysis narrows *WNT16* locus from linkage disequilibrium (LD) blocks. Linkage disequilibrium (LD) blocks represent correlations between SNPs. The red intensity represents strength of the  $r^2$  value calculated from 1000 A. SNPs in high LD ( $r^2_{EA} \geq 0.8$ ) with the *WNT16* index SNP in European populations. Asterisks (\*) represent the lead SNP identified in the African ancestry meta-analysis. Hyphens (-) represent the index SNP identified by the GEFOS Consortium as the lead SNP; a black box is drawn around SNPs in high LD with the



JBMR\_4220\_Fig1.tif



JBMR\_4220\_Fig2.tif